Study Finds High Rate of Co-Infections Among Lyme-Positive Patients
A retrospective cohort study of over 193,000 U.S. patients found that 29.5% of those testing positive for the Lyme disease bacterium also tested positive for at least one other tick-borne pathogen, such as Anaplasma, Babesia, or Ehrlichia. Co-infection rates varied by region, with the Northeast highest at 31.1% and the West lowest at 13.6%. Researchers advise clinicians to consider other tick-borne infections even when Lyme disease symptoms are typical, as treatment approaches may differ.
The study analyzed over 193,000 U.S. patients tested for tick-borne diseases, finding that 5% were positive for Borrelia burgdorferi. Among those, nearly a third also had antibodies for Anaplasma, Babesia, or Ehrlichia. Regional differences were stark, with the Northeast showing a 31.1% co-infection rate compared to 13.6% in the West.
Researchers note that while a positive antibody test doesn't confirm active co-infection, it signals potential concurrent or past exposure. The geographic spread of tick species is shifting, complicating traditional regional assumptions. Treatment implications are significant, as doxycycline covers Lyme and anaplasmosis but not babesiosis, requiring clinicians to consider broader testing strategies.
This finding could significantly alter clinical practice for patients with suspected Lyme disease, as misdiagnosing a co-infection may lead to ineffective treatment and prolonged illness. Patients in the Northeast and Midwest may face the highest risk of overlooked co-infections. The study may encourage more comprehensive tick-borne testing panels, potentially increasing healthcare costs but improving outcomes. Public awareness could grow regarding the complexity of tick bites, prompting more cautious prevention measures and earlier, broader diagnostic workups in endemic regions.